You are here: Home » News-ANI » Business
Business Standard

Dr Reddy's Labs expands portfolio with acquisition of ANDAs portfolio in US


has signed a definitive agreement to acquire a portfolio of 42 approved, non-marketed Abbreviated New Drug Applications (ANDAs) in the

The portfolio includes more than 30 These products will require and could be launched in the next one or two years.

"The acquisition is in line with our stated strategy to significantly enhance our portfolio in our chosen growth markets," said company's

"This transaction will help augment our injectables product portfolio in the U.S. market and globally," he added.

The value of total addressable market for these products in the was about 645 million dollars (about Rs 4,470 crore) last calendar year, according to IQVIA.

IQVIA, earlier known as and IMS Health Inc, is an American multinational company serving the combined industries of and clinical research.


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Mon, April 15 2019. 11:21 IST